MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients

Maria Lina Tornesello; Luigi Buonaguro; Medea Cristillo; Bennon Biryahwaho; Robert Downing; Angelo Hatzakis; Elvio Alessi; Marco Cusini; Vincenzo Ruocco; Enza Viviano; Nino Romano; Edward Katongole-Mbidde; Franco M. Buonaguro

doi:10.3109/1354750X.2010.525664

MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients

Maria Lina Tornesello, Luigi Buonaguro, Medea Cristillo, Bennon Biryahwaho, Robert Downing, Angelo Hatzakis, Elvio Alessi, Marco Cusini, Vincenzo Ruocco, Enza Viviano, Nino Romano, Edward Katongole-Mbidde, Franco M. Buonaguro

Research output: Contribution to journal › Article › peer-review

Abstract

A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene for the development of classic KS in Caucasian patients.

Original language	English
Pages (from-to)	42-50
Number of pages	9
Journal	Biomarkers
Volume	16
Issue number	1
DOIs	https://doi.org/10.3109/1354750X.2010.525664
Publication status	Published - Feb 2011

Keywords

CDKN1A
Genetic polymorphisms
Kaposi's sarcoma.
MDM2

ASJC Scopus subject areas

Biochemistry
Clinical Biochemistry
Health, Toxicology and Mutagenesis

Access to Document

10.3109/1354750X.2010.525664

Fingerprint Dive into the research topics of 'MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients'. Together they form a unique fingerprint.

Cite this

Tornesello, M. L., Buonaguro, L., Cristillo, M., Biryahwaho, B., Downing, R., Hatzakis, A., Alessi, E., Cusini, M., Ruocco, V., Viviano, E., Romano, N., Katongole-Mbidde, E., & Buonaguro, F. M. (2011). MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. Biomarkers, 16(1), 42-50. https://doi.org/10.3109/1354750X.2010.525664

MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. / Tornesello, Maria Lina ; Buonaguro, Luigi; Cristillo, Medea; Biryahwaho, Bennon; Downing, Robert; Hatzakis, Angelo; Alessi, Elvio; Cusini, Marco; Ruocco, Vincenzo; Viviano, Enza; Romano, Nino; Katongole-Mbidde, Edward; Buonaguro, Franco M.

In: Biomarkers, Vol. 16, No. 1, 02.2011, p. 42-50.

Research output: Contribution to journal › Article › peer-review

Tornesello, Maria Lina ; Buonaguro, Luigi ; Cristillo, Medea ; Biryahwaho, Bennon ; Downing, Robert ; Hatzakis, Angelo ; Alessi, Elvio ; Cusini, Marco ; Ruocco, Vincenzo ; Viviano, Enza ; Romano, Nino ; Katongole-Mbidde, Edward ; Buonaguro, Franco M. / MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. In: Biomarkers. 2011 ; Vol. 16, No. 1. pp. 42-50.

@article{6cbc0b7707c74a0faec337e92b5035da,

title = "MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients",

abstract = "A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene for the development of classic KS in Caucasian patients.",

keywords = "CDKN1A, Genetic polymorphisms, Kaposi's sarcoma., MDM2",

author = "Tornesello, {Maria Lina} and Luigi Buonaguro and Medea Cristillo and Bennon Biryahwaho and Robert Downing and Angelo Hatzakis and Elvio Alessi and Marco Cusini and Vincenzo Ruocco and Enza Viviano and Nino Romano and Edward Katongole-Mbidde and Buonaguro, {Franco M.}",

year = "2011",

month = feb,

doi = "10.3109/1354750X.2010.525664",

language = "English",

volume = "16",

pages = "42--50",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients

AU - Tornesello, Maria Lina

AU - Buonaguro, Luigi

AU - Cristillo, Medea

AU - Biryahwaho, Bennon

AU - Downing, Robert

AU - Hatzakis, Angelo

AU - Alessi, Elvio

AU - Cusini, Marco

AU - Ruocco, Vincenzo

AU - Viviano, Enza

AU - Romano, Nino

AU - Katongole-Mbidde, Edward

AU - Buonaguro, Franco M.

PY - 2011/2

Y1 - 2011/2

N2 - A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene for the development of classic KS in Caucasian patients.

AB - A single-nucleotide polymorphism in the MDM2 promoter (SNP309; rs2279744) causes elevated transcription of this major negative regulator of p53 in several cancer types. We investigated MDM2 SNP309 and CDKN1A (p21/Waf1/Cip1) codon 31 (rs1801270) polymorphisms in 86 cases of cutaneous Kaposi's sarcoma (KS) from African and Caucasian patients, and 210 healthy controls. A significant increase of the MDM2 SNP309 T/G genotype was observed among classic KS cases (odds ratio 2.38, 95% confidence interval 1.0-5.5). Frequencies of CDKN1A codon 31 genotypes were not significantly different between cases and controls. The results suggest that the MDM2 SNP309 G allele may act as a susceptibility gene for the development of classic KS in Caucasian patients.

KW - CDKN1A

KW - Genetic polymorphisms

KW - Kaposi's sarcoma.

KW - MDM2

UR - http://www.scopus.com/inward/record.url?scp=79251528612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251528612&partnerID=8YFLogxK

U2 - 10.3109/1354750X.2010.525664

DO - 10.3109/1354750X.2010.525664

M3 - Article

C2 - 20979563

AN - SCOPUS:79251528612

VL - 16

SP - 42

EP - 50

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 1

ER -